|
|
 |
|
Viewing report
|
|
|
|
Acorda Therapeutics, Inc.: Company Profile and SWOT Analysis
iCD Research, Sep 2011, Pages: 25
Synopsis
ICD Research's 'Acorda Therapeutics, Inc.: Company Profile and SWOT Analysis' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, competitor benchmarking data, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
Summary
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
ICD Research's 'Acorda Therapeutics, Inc.: Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about Acorda Therapeutics, Inc. for business intelligence requirements
- Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
- Provides analysis on financial ratios along with a competitor benchmarking section
- The profile also contains information on business operations, company history, major products and services, prospects, key competitors, key employees, locations and subsidiaries
Reasons To Buy
- Quickly enhance your understanding of the company
- Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
- Increase business/sales activities by understanding your competitors’ businesses better
- Recognize potential partnerships and suppliers
- Obtain yearly profitability figures
Key Highlights
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in identification, development and commercialization of therapies for spinal cord injury, multiple sclerosis and other froms of nervous system disorders. The company’s markets a wide range of tablets such as Ampyra (dalfampridine) extended release tablets, to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets which are the short-acting drugs approved for the management of spasticity. Further, the company has three preclinical programs namely, Chondriotinase, Remyelinating antibodies and Neuregulins focused on novel approaches to repair damaged components of the CNS. The company is headquartered in New York, the US.
|
|
|
|
